Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

781
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
781
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Human haematopoietic stem cells remember inflammatory stress.

Nature·2026
Same author

Initial leukemic epigenomic state determines hypomethylating agent response.

Nature communications·2026
Same author

MYB activity drives emergent enhancer activation and enhancer-promoter interactions in acute lymphoblastic leukemia.

Blood·2026
Same author

Gain and Loss of FLT3 Mutations in Patients with Acute Myeloid Leukemia: A Noninterventional Cohort Study (CLEVO).

Oncology and therapy·2026
Same author

Patient involvement in the design of ALIDHE: a study of ivosidenib + azacitidine in newly diagnosed <i>IDH1</i> mutant AML.

Future oncology (London, England)·2025

Related Experiment Video

Updated: Jan 2, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.4K

The Graft-Versus-Leukemia Effect in AML.

Connor Sweeney1,2, Paresh Vyas1,2

  • 1MRC Molecular Haematology Unit, Oxford Biomedical Research Centre, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.

Frontiers in Oncology
|December 6, 2019
PubMed
Summary

Allogeneic stem cell transplants (allo-SCT) use donor immune cells to fight leukemia, but can cause graft-versus-host disease (GvHD). Understanding the specific antigens driving graft-versus-leukemia (GvL) and GvHD is key to improving cancer immunotherapy.

Keywords:
T cellsacute myeloid leukemiaantigensgraft-versus-host diseasegraft-versus-leukemiastem cell transplantation

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

581
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Related Experiment Videos

Last Updated: Jan 2, 2026

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice
10:02

Intra-Peritoneal Transplantation for Generating Acute Myeloid Leukemia in Mice

Published on: January 6, 2023

2.4K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

581
Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.6K

Area of Science:

  • Immunotherapy
  • Hematology
  • Oncology

Background:

  • Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a primary cellular immunotherapy for cancer.
  • It is the most effective anti-leukemic therapy for acute myeloid leukemia (AML), particularly for intermediate and poor-risk patients.
  • The graft-versus-leukemia (GvL) effect, mediated by donor immune cells, eliminates residual leukemia cells post-chemotherapy.

Purpose of the Study:

  • To address the critical need for understanding the cellular and molecular basis of GvL and graft-versus-host disease (GvHD).
  • To identify specific antigens driving GvL and GvHD to improve allo-SCT outcomes.
  • To explore the potential for decoupling GvL and GvHD for enhanced anti-leukemic responses with reduced toxicity.

Main Methods:

  • The abstract does not detail specific methods but discusses the need for understanding antigenic basis of immune responses.
  • Focus is on identifying antigens responsible for GvL and GvHD.

Main Results:

  • GvHD and GvL often co-occur, with GvHD treatment immunosuppression limiting the full therapeutic benefit of allo-SCT.
  • Curative responses to allo-SCT and GvHD do not always coincide, suggesting these responses can be separated.
  • The antigenic basis of GvL and GvHD remains largely unknown in most patients.

Conclusions:

  • Further progress in enhancing GvL while minimizing GvHD requires a deeper understanding of their underlying cellular and molecular mechanisms.
  • Identifying specific antigens could guide donor selection and enable targeted strengthening of anti-leukemic responses.
  • Harnessing GvL without GvHD could significantly improve the efficacy and safety of allo-SCT for AML patients.